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THE IMPACT OF THE IPLEDGE PROGRAM ON ISOTRETINOIN FETAL 
EXPOSURE
Shin J1, Niu F2, Wong L3, Yoshinaga MA2, McCombs J1, Cheetham CT2
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OBJECTIVES: The objective of this retrospective cohort study is to analyze the effect 
of the iPLEDGE program on rates of fetal exposure to isotretinoin in females of child-
bearing potential (FCBP). METHODS: This study used databases from Kaiser Perma-
nente Southern California, which includes prescription records, laboratory results, and 
outpatient/inpatient visit procedures and diagnoses. All FCBP who ﬁlled isotretinoin 
during the study period of March 1, 2004 to February 29, 2008 were identiﬁed. Chart 
review was performed to validate pregnancy in patients with positive pregnancy 
indicators. The analysis was performed at the treatment course-level. Treatment 
courses were excluded if they straddled both before and after iPLEDGE implementa-
tion on March 1, 2006. Poisson regression was used to analyze the impact of iPLEDGE 
on the rate of fetal exposures, controlling for age, prior utilization of acne prescription 
medications, and other risk factors. RESULTS: There were a total of 8 fetal exposures 
during 2585 treatment courses before iPLEDGE and 6 fetal exposures during 1595 
treatment courses after iPLEDGE implementation. Unadjusted fetal exposure rates 
increased slightly from 3.09 per 1000 treatment courses to 3.76 per 1000 treatment 
courses with iPLEDGE. When controlling for other factors, the rate ratio for fetal 
exposure after compared to before iPLEDGE implementation was 0.45 [95%CI: 0.31, 
0.67] in FCBP less than 21 years of age. In FCBP greater than or equal to 21 years 
of age, the rate ratio was 1.46 [95%CI: 1.10, 1.94]. CONCLUSIONS: The risk of 
fetal exposure among treatment courses ﬁlled by younger FCBP signiﬁcantly decreased 
by 55% after the implementation of iPLEDGE. In contrast, the risk of fetal exposure 
signiﬁcantly increased by 46% after iPLEDGE began among treatment courses ﬁlled 
by older FCBP. Our results suggest that the iPLEDGE program had a differential effect 
on the rate of fetal exposures to isotretinoin depending on patient age group.
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DEVELOPMENT OF A DECISION-ANALYTIC MODEL FOR GLAUCOMA 
PROGRESSION USING PATIENT LEVEL DATA FROM THREE LARGE 
RANDOMIZED CONTROLLED TRIALS
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OBJECTIVES: Evaluation of cost-effectiveness for chronic disease treatment requires 
development and validation of a model of disease progression using “real world” data. 
We constructed a Markov model using patient-level data from three large studies of 
glaucoma treatment and conducted internal validation. METHODS: Glaucoma sever-
ity and disease progression were deﬁned clinically in terms of visual ﬁeld loss expressed 
as mean deviation (MD) measured in decibels (dB). Patient level data for the model 
came from the Collaborative Initial Glaucoma Treatment Study (CIGTS n = 574), the 
Ocular Hypertension Treatment Study (OHTS n = 1,546), and the Advanced Glau-
coma Intervention Study (AGIS n = 580). Our initial model was limited to the pattern 
of progression over seven years. Transition probabilities for the Markov model were 
calculated for each combination of year and MD. The model was estimated with 
TreeAge software using a microsimulation approach. Internal validation was con-
ducted by comparing the predicted value of hypothetical participants to that of the 
actual study participants. For this purpose, a clinically signiﬁcant difference was 
considered to be 3 decibels (dB) of MD. RESULTS: Three variables—age, race, and 
starting MD—were most strongly associated with change in MD. Predicted values 
from the model were regressed on actual study results. The R2 for the right eye was 
0.72, and for the left 0.70. Of those participants outside of a 3 dB band around 
“perfect” prediction, over 85% had less severe disease at year 7 than predicted by the 
model. CONCLUSIONS: Our initial results indicate that the glaucoma progression 
model properly predicts the result of disease progression in over 80% of “partici-
pants”. This suggests that our modeling approach provides a reasonable reﬂection of 
real world progression and provides a useful tool for researchers and policy makers. 
Once completed, this model will provide a tool for evaluation of pressure lowering 
medications.
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EFFECT OF BIVALIRUDIN ON CLINICAL OUTCOMES OF STEMI 
PATIENTS IN AN OBSERVATIONAL DATASET
Kessler DP
Stanford University, Stanford, CA, USA
OBJECTIVES: Hospitals are increasingly focused on reducing patient harm associated 
with anticoagulant therapy. However, because treatment decisions may be based on 
prognosis, estimates of treatment effects obtained from observational data may suffer 
from “confounding by indication.” To address this concern, we used a grouped-
treatment approach to determine the impact of choice of anticoagulant on the risk of 
severe bleeding and in-hospital death in patients undergoing percutaneous coronary 
intervention (PCI). METHODS: We analyzed the Premier Perspective database on 
patients aged ≥18 years admitted to Premier hospitals with a diagnosis of ST-elevated 
myocardial infarction (STEMI) and ≥1 procedure code for PCI between Q12004 and 
Q12008 (N = 71,296). We constructed individual-level models of severe bleeding and 
in-hospital death (all-cause) similar to those in a conventional multivariate analysis, 
except that each individual’s actual treatment variables were replaced with grouped-
treatment variables (the proportion of patients receiving each treatment at the hospital/
year in which treatment occurred). We used logistic regression to assess the impact of 
the likelihood of treatment with bivalirudin or heparin ± a glycoprotein IIb/IIIa inhibi-
tor on severe bleeding and in-hospital death, controlling for other treatments (includ-
ing stent use, other drug use, CABG); patient demographics, concomitant diagnoses, 
insurance status, physician specialty; and hospital region, size, teaching status. We 
calculated conﬁdence intervals allowing for the clustering of errors at the hospital/year 
level. RESULTS: Bivalirudin treatment was associated with a signiﬁcantly reduced risk 
of severe bleeding (OR = 0.45, 95% CI = 0.21–0.97) and a reduced risk of in-hospital 
mortality (OR = 0.83, 95% CI 0.54–1.28) compared to heparin+GPI. CONCLU-
SIONS: Increasing the proportion of a hospital’s patients treated with bivalirudin was 
associated with a signiﬁcant reduction in severe bleeding. These results demonstrate 
the beneﬁts of bivalirudin for clinical outcomes in a real-world setting.
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POSTMARKETING SAFETY EVALUATION OF ALISKIREN 
HEMIFUMARATE, A NEW MOLECULAR ENTITY
Ali AK
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OBJECTIVES: To evaluate the safety proﬁle of aliskiren by calculating the adjusted 
reporting ratios of speciﬁc adverse events. METHODS: The FDA’s Adverse Event 
Reporting System (AERS) data are utilized to conduct this retrospective pharmaco-
vigilance study. Adverse event (AE) reports submitted to the AERS during the period 
of January 2007 through December 2008 are included in the analysis. Systematic 
Multi-item Gamma Poisson Shrinker (MGPS) data mining algorithm is applied to 
calculate the adjusted reporting ratios (ARR) of AE, which estimated by the Empiric 
Bayes Geometric Mean (EBGM) values and their 95% conﬁdence intervals (95%CI). 
EBGM values of >2.0 are considered as safety signals signiﬁcant for regulatory deci-
sions. Reports for aliskiren and other drugs affecting the Renin-Angiotensin-Aldoste-
rone System (RAAS) are identiﬁed using the verbatim names for each individual class 
members. Reports for speciﬁc AE are identiﬁed by the utilized Preferred Terms of the 
Medical Dictionary for Regulatory Activities coding scheme (MedDRA PT) in the 
AERS. RESULTS: During the study period, a total number of 2154 reports for aliski-
ren are received by the AERS. Seventy four percent (1592) of these reports had valid 
MedDRA terms, and included in the analysis. Compared to other RAAS modulators, 
aliskiren was associated with the highest ARR for angioedema (EBGM 3.9, 95%CI 
3.2–4.7), renal dysfunction (EBGM 3.4, 95%CI 2.6–4.5), dry cough (EBGM 11.0, 
95%CI 7.8–14.2), and diarrhoea (EBGM 4.3, 95%CI 3.2–5.8). Aliskiren ranked the 
second after aldosterone antagonists in hyperkalaemia (EBGM 7.4, 95%CI 3.4–13.0). 
CONCLUSIONS: Treatment with aliskiren may be associated with angioedema and 
renal dysfunction. Patients with signs and symptoms of angioedema should stop 
aliskiren and seek urgent medical help. Aliskiren should not be used by patients with 
risks of renal dysfunction. While additional longitudinal studies and clinical awareness 
is warranted, regulatory changes in product label and safety communications, e.g. 
dear-health care-professional letters are recommended.
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ESTIMATION OF ADVERSE EVENTS RELATED WITH MEDICARE 
PATIENTS WHO UNDERWENT HIP FRACTURE SURGERY AND 
SUFFERED VENOUS THROMBOEMBOLISM VERSUS NO VENOUS 
THROMBOEMBOLISM
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OBJECTIVES: To estimate mortality, re-hospitalization and bleeding 30 days after a 
venous thromboembolism (VTE) event in patients following hip fracture surgery and 
to compare the outcomes with patients without VTE. METHODS: Based on 2005–
2007 national Medicare claims, all patients who underwent hip fracture surgery were 
identiﬁed. Thirty days follow-up event rates for patients who had a VTE event during 
their initial hospitalization were calculated. Events were compared between patients 
